Statutory Earnings May Not Be The Best Way To Understand Mediwelcome Healthcare Management & Technology's (HKG:2159) True Position
Even though Mediwelcome Healthcare Management & Technology Inc. (HKG:2159) posted strong earnings recently, the stock hasn't reacted in a large way. We decided to have a deeper look, and we believe that investors might be worried about several concerning factors that we found.
Zooming In On Mediwelcome Healthcare Management & Technology's Earnings
In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. This ratio tells us how much of a company's profit is not backed by free cashflow.
That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".
For the year to June 2026, Mediwelcome Healthcare Management & Technology had an accrual ratio of 0.50. That means it didn't generate anywhere near enough free cash flow to match its profit. Statistically speaking, that's a real negative for future earnings. In fact, it had free cash flow of CN¥4.3m in the last year, which was a lot less than its statutory profit of CN¥34.0m. Notably, Mediwelcome Healthcare Management & Technology had negative free cash flow last year, so the CN¥4.3m it produced this year was a welcome improvement. However, that's not all there is to consider. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio. The good news for shareholders is that Mediwelcome Healthcare Management & Technology's accrual ratio was much better last year, so this year's poor reading might simply be a case of a short term mismatch between profit and FCF. As a result, some shareholders may be looking for stronger cash conversion in the current year.
See our latest analysis for Mediwelcome Healthcare Management & Technology
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Mediwelcome Healthcare Management & Technology.
The Impact Of Unusual Items On Profit
Given the accrual ratio, it's not overly surprising that Mediwelcome Healthcare Management & Technology's profit was boosted by unusual items worth CN¥8.7m in the last twelve months. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. Mediwelcome Healthcare Management & Technology had a rather significant contribution from unusual items relative to its profit to June 2026. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.
Our Take On Mediwelcome Healthcare Management & Technology's Profit Performance
Mediwelcome Healthcare Management & Technology had a weak accrual ratio, but its profit did receive a boost from unusual items. Considering all this we'd argue Mediwelcome Healthcare Management & Technology's profits probably give an overly generous impression of its sustainable level of profitability. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Case in point: We've spotted 2 warning signs for Mediwelcome Healthcare Management & Technology you should be mindful of and 1 of these makes us a bit uncomfortable.
Our examination of Mediwelcome Healthcare Management & Technology has focussed on certain factors that can make its earnings look better than they are. And, on that basis, we are somewhat skeptical. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.